# EDGAR Filing Document

**Accession Number:** 0002053118
**File Stem:** 0001214659-25-015578
**Filing Date:** 2025-10
**Character Count:** 59992
**Document Hash:** c7502a2912abadd69e554e152fa382ca
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001214659-25-015578.hdr.sgml**: 20251030

**ACCESSION NUMBER**: 0001214659-25-015578

**CONFORMED SUBMISSION TYPE**: 1-U

**PUBLIC DOCUMENT COUNT**: 4

**CONFORMED PERIOD OF REPORT**: 20250930

**ITEM INFORMATION**: Fundamental Changes

**ITEM INFORMATION**: Certain Unregistered Sales of Equity Securities

**FILED AS OF DATE**: 20251030

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** FirstVitals Inc.
- **CENTRAL INDEX KEY:** 0002053118
- **STANDARD INDUSTRIAL CLASSIFICATION:** SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 994891274
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 1-U
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 24R-01008
- **FILM NUMBER:** 251434736

**BUSINESS ADDRESS:**
- **STREET 1:** 2605 CAMINO TASSAJARA
- **STREET 2:** UNIT 2500
- **CITY:** DANVILLE
- **STATE:** CA
- **ZIP:** 94526
- **BUSINESS PHONE:** 8009228844

**MAIL ADDRESS:**
- **STREET 1:** 2605 CAMINO TASSAJARA
- **STREET 2:** UNIT 2500
- **CITY:** DANVILLE
- **STATE:** CA
- **ZIP:** 94526

**UNITED STATES** 

**SECURITIES AND EXCHANGE COMMISSION**

 **Washington, D.C 2049**

**FORM 1-U**

**CURRENT REPORT PURSUANT TO REGULATION A**

**September 30, 2025**

(date of earliest event reported)

For

**FIRSTVITALS, INC.** 

A Delaware Corporation I.R.S. E.I.N. 99-4891274

2605 Camino Tassajara #2500 \| Danville, CA 94526

800-922-8844 ext 8888

ernie.lee@firstvitals.com

<br> COMMON STOCK

**<u>Item 1. Fundamental Changes</u>**

<u>Share Purchase Agreements with IntroMedic Co., Ltd. and Port Hamilton Investment Association.</u>

On September 30, 2025, FirstVitals, Inc. (the "***Company***") entered into two Share Purchase Agreements with the purpose of acquiring a majority interest in IntroMedic Co., Ltd. a corporation incorporated under the laws of the Republic of Korea ("***IntroMedic***"). IntroMedic is a manufacturer and distributor of the MiroCam, a video capsule used for endoscopy procedures. In the aggregate, the Company will acquire 51.1% of the effective voting rights of the Company. This effective control is comprised of ownership of 43.2% of the outstanding common shares of the Company and acquisition of the voting rights of an additional 9.8% of the common shares.

Pursuant to the first Share Purchase Agreement, the Company will acquire 32,719,500 newly issued common shares (representing 43.2% of the outstanding common stock) from IntroMedic in three tranches. On November 14, 2025, the Company will acquire 13,333,333 common shares for 3,999,999,900 Korean Won (KRW)(approximately $2,857,143.00). All conversions of KRW to USD$ are as of September 30, 2025. On December 30, 2025, the Company will acquire 15,386,167 common shares for KRW 4,615,850,100 (or approximately $3,297,035.00) and 4,000,000 common shares for KRW 1,200,000,000 (approximately $857,143.00). The company has deposited 430,000,000 (approximately $307,142.00).

Pursuant to the second Share Purchase Agreement, the Company will acquire 2,727,273 outstanding shares of IntroMedic from Port Hamilton Investment Association ("***PHIA***"), and the voting rights to 1,489,594 common shares of IntroMedic retained by PHIA. The purchase price for these shares and rights is KRW 3,000,000,000 (or $2,142,857.00).

There are various conditions that must be satisfied on or before October 30, 2025 prior to the Company's obligation to acquire the common shares of IntroMedic described herein (unless waived by the Company). These include 1) delivery of the proxy voting agreement by PHIA associated with the 1,489,594 common shares of IntroMedic; 2) resignation letters from the existing Board of Directors and auditor of IntroMedic; 3) delivery of a certificate indicating all IntroMedic taxes have been paid; 4) delivery of a statement of liabilities of IntroMedic; and 5) delivery of a IntroMedic corporate resolution authorizing a shareholder meeting to appoint directors and an auditor nominated by the Company. IntroMedic has agreed not to enter into any material contracts or allow any disbursements exceeding KRW 6,750,000 unless approved by the Company. IntroMedic also warrants that the Company shall have a cash balance no less than KRW 530,000,000 as of November 15, 2025. Separately, prior to November 12, 2025, PHIA has agreed to acquire 1,807,228 common shares of IntroMedic from Spring Nine Co., Ltd, currently IntroMedic's second largest shareholder, and assign all voting rights associated with those common shares to the Company.

If IntroMedic shall breach the Share Purchase Agreement, the Company shall be entitled to damages, and all funds paid by the Company shall be returned to the Company with statutory interest at the rate of 6% (six percent) per annum and PHIA shall assign and transfer all its IntroMedic shares to the Company. If the Company shall breach a Share Purchase Agreement, it shall be liable for any damages and in addition, all funds paid by the Company shall be forfeited and applied as consideration for the purchase of the IntroMedic shares held by PHIA. Both Share Purchase Agreements are governed by the laws of the Republic of Korea.

The Company was listed on the KOSDAQ Market of the Korea Exchange on December 19, 2013. However, on May 13, 2025, the KOSDAQ Listing Committee resolved to delist the Company. The Company filed an injunction with the Seoul Southern District Court on May 14, 2025, to suspend the effectiveness of the delisting decision. Until the court rules on the injunction, trading of the shares remains suspended.

**Item 8. Certain Unregistered Sales of Equity Securities**

<u>Promissory Note with Dr. Steven Gest</u>

The Company issued a Series A Convertible Promissory Note to Dr. Steven Gest on October 2, 2025, in the amount of $250,000 (the "Series A Note"). This Series A Note accrues interest at ten percent (10%) per annum and the principal and interest shall be due on March 17, 2028. This Series A Note is convertible by the Company into common shares of the Company upon an initial public offering or upon an equity financing transaction that raises in excess of $30 million dollars. The conversion price would be discounted at fifty percent (50%) of the common share price established in the initial public offering or equity financing transaction. This Series A Note was issued pursuant to an exemption from registration found in Section 4(a)(2) and Regulation D Rule 506(b). Dr. Steven Gest is an accredited investor and the Company did not make a general solicitation of the Series A Note.

**<u>EXHIBITS</u>**

**<u>Exhibit Index</u>**

---

| | |
|:---|:---|
| **EX1U 1.2** | **September 30, 2025 Share Purchase Agreement with IntroMedic Co., Ltd.** |
| **EX1U 1.3** | **September 30, 2025 Share Purchase Agreement with Port Hamilton Investment Association** |
| **EX1U 6.7** | **October 2, 2025 Series A Convertible Promissory Note to Dr. Steven Gest.** |

---

**<u>SIGNATURES</u>**

Pursuant to the requirements of Regulation A, the issuer has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

**FirstVitals, Inc.** 

(Exact name of issuer as specified in its charter)

By: /<u>s/ Ernest Lee</u>

Chief Executive Officer

Chairman of the Board of Directors

October 30, 2025

## Ex1U-1

**Exhibit 1U-1.2**

**SHARE SUBSCRIPTION AGREEMENT**

This Agreement is entered into on September 30, 2025, by and between:

**Company**: Intromedic Co., Ltd., a corporation incorporated under the laws of the Republic of Korea, having its principal office at #1105–1106, 41, Digital-ro 31-gil, Guro- gu, Seoul, Republic of Korea (CEO: Yong Seok Cho) (hereinafter, the "Company").

**Investor**: FirstVitals, Inc., a corporation incorporated under the laws of the State of Delaware, U.S.A., having its principal office at 8A The Green, Dover, Delaware 19901 (Representative: Ernie G. Lee) (hereinafter, the "Investor").

**RECITALS**

1. The Company was listed on the KOSDAQ Market of the Korea Exchange on December 19, 2013. On May 13, 2025, the KOSDAQ Listing Committee resolved to delist the Company. The Company filed an injunction with the Seoul Southern District Court on May 14, 2025, seeking suspension of such decision. The case is pending, and trading of shares remains suspended.

2. Pursuant to Article 10(2)(vi) and (ix) of the Articles of Incorporation, the Company has resolved by its board to issue new shares to the Investor by way of third- party allotment, in order to improve its financial structure and develop new

technology.

3. The total authorized shares of the Company are 3,000,000,000 (par value KRW 100 each). As of the date hereof, the total issued shares are 42,997,901 ordinary voting shares.

4. Port Hamilton Investment Association ("PHIA") is a partnership organized and existing under the laws of the Republic of Korea and is currently the largest shareholder of the Company, holding 4,216,867 shares out of the Company's total issued shares of 42,997,901.

**Article 1 (Purpose)**

This Agreement is executed for the issuance and subscription of new ordinary voting shares to the Investor by way of third-party allotment, pursuant to Article 10(2)(vi) and

(ix) of the Articles of Incorporation, to improve the Company's financial structure and develop new technology.

**Article 2 (Issuance of First New Shares)**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1. Type: Ordinary registered voting shares (par value KRW 100 each).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2. Number: 13,333,333 shares.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3. Issue Price: KRW 300 per share.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4. Total Subscription Price: KRW3,999,999,900

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5. Payment Date: November 14, 2025.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6. Subscription Account: KB Kookmin Bank, Account No. 024837-04-009566, Account Holder: Intromedic Co., Ltd.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7. Payment Method: Wire transfer in KRW on the payment date.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8. Security Deposit: To secure payment, the Investor shall deposit KRW 430,000,000 by September 30, 2025 into the Investor's virtual
account for Foreign Direct Investment opened by KB Kookmin Bank. Such deposits shall be transferred to the subscription account on the
payment date as part of the subscription price. For the avoidance of doubt, Investor shall deposit the remaining ₩3,569,999,900
into the Investor's domestic account by no later than November 12, 2025.

[Investor's Domestic Account]

Bank Account Holder

KB Kookmin Bank FirstVitals, Inc.

**Article 3 (Issuance of Second New Shares)**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1. Type: Ordinary registered voting shares (par value KRW 100 each).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2. Number: 15,386,167 shares.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3. Issue Price: KRW 300 per share.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4. Total Subscription Price: KRW 4,615,850,100

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5. Payment Date: December 30, 2025.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6. Subscription Account: KB Kookmin Bank, Account No. 024868-11-020769, Account Holder: Intromedic Co., Ltd.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7. Payment Method: Wire transfer in KRW on the payment date.

**Article 4 (Issuance of Third New Shares)**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1. Type: Ordinary registered voting shares (par value KRW 100 each).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2. Number: 4,000,000 shares.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3. Issue Price: KRW 300 per share.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4. Total Subscription Price: KRW 1,200,000,000.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5. Payment Date: December 30, 2025.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6. Subscription Account: KB Kookmin Bank, Account No. 024868-11-020769, Account Holder: Intromedic Co., Ltd.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7. Payment Method: Wire transfer in KRW on the payment date.

**Article 5 (Bonds with Warrants)**

The Company and the Investor agree to negotiate in good faith the terms and conditions for the issuance of bonds with warrants by the Company pursuant to Articles 516-2 through 516-6 of the Korean Commercial Code. In the event the parties reach agreement on such terms, the Company shall cause such issuance to be included as an agenda item at both the meeting of the board of directors and the extraordinary general meeting of shareholders scheduled for November 14, 2025. If the parties fail to reach agreement on the terms of the bonds with warrants, they shall in good faith discuss the issuance of new shares.

**Article 6 (Conditions Precedent)**

6.1 By October 30, 2025, the Company shall perform the following, unless waived in writing by the Investor:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) Delivery of an irrevocable proxy with seal certificate permanently delegating voting rights of Port Hamilton's shares to the
Investor's designated agent.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) Delivery to the Investor's designated agent of resignation letters of directors and auditors with seal certificates (by November
12, 2025).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii) Delivery to the Investor's designated agent of tax payment certificates evidencing full payment of all taxes.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iv) Delivery to the Investor's designated agent of a statement of liabilities as of the Agreement date, including all debts, unpaid
wages, notes, and checks.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(v) Board resolution to convene an extraordinary shareholders' meeting on November 14, 2025, to appoint directors and auditor nominated
by the Investor, and notice thereof.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(vi) Board resolutions approving the issuances under Articles 2–4.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(vii) Extraordinary shareholders' resolutions dated November 14, 2025 approving each of the directors and auditor nominated by the
Investor.

6.2 If the Company fails to satisfy the conditions, the Investor may refuse subscription and terminate this Agreement.

6.3 If the nominees are not appointed at the extraordinary shareholders' meeting on November 14, 2025, the Investor may terminate
this Agreement and such will be deemed as a material breach by the Company.

**Article 7 (Covenants, Representations and Warranties of the Company)**

&nbsp;&nbsp;&nbsp;&nbsp;7.1 As of the date of this Agreement, the Company represents and warrants that:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1. It is duly incorporated under Korean law, has all necessary permits, and is validly existing.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2. It has completed all internal procedures necessary to grant subscription rights to the Investor by third-party allotment, with no
legal impediments.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3. It has no liabilities other than those disclosed in the statement of liabilities, and no outstanding notes or checks.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4. It has no unpaid national or local taxes, and all documents under Article 6 are genuine.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5. Miropet Co., Ltd. has failed to perform obligations under distribution agreements with the Company, and the Company retains the right
to terminate such agreements.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6. The Share Purchase Agreement, the Voting Rights Proxy Agreement, and the Account Management Agreement entered into by and between
the Investor and PHIA on the date hereof shall remain valid and in full force and effect as of November 15, 2025, and shall not have been
terminated prior to such date as a result of any default by PHIA.

7.2 The Company hereby represents, warrants, and covenants to the Investor that, unless and until it has obtained the Investor's prior explicit written consent, it shall not:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1. Make any new disbursement to any person, including any affiliate, in an aggregate amount exceeding KRW 6,750,000;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2. Enter into any new contract, whether oral or written, including, without limitation, any customer sales agreement, vendor purchase
agreement, lease agreement, or employment agreement; or

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3. Commence any employment, contractor, consulting, advisory, or other similar relationship with any person.

7.3 As of November 15, 2025, the Company's remaining cash balance shall be no less than KRW 530,000,000 (the "Cash Balance"); provided, however, that the Cash Balance threshold shall be reduced by an amount equal to any shortfall resulting from accounts receivable that, through no fault of the Company, have not been paid to or received by the Company.

7.4 If these covenants and/or warranties prove untrue and frustrate the purpose of this Agreement, such will be deemed a material breach by the Company and the Investor may terminate within 10 days and claim damages.

**Article 8 (Representations of the Investor)**

8.1 The Investor represents that it is duly incorporated under Delaware law, has obtained all approvals, and faces no legal impediments
in acquiring subscription rights.

8.2 Breach entitles the Company to terminate within 10 days and claim damages.

**Article 9 (Costs and Taxes)**

Each party shall bear its own costs and taxes arising under this Agreement as of the payment date.

**Article 10 (Termination)**

10. 1 Either party may terminate this Agreement by written notice if the other breaches, and the breaching party shall compensate damages.

10.2 In the event the Investor terminates this Agreement as a result of a breach by the Company or PHIA, the Company agrees that, in addition
to Section 10.1, all funds paid by the Investor shall be returned to the Investor together with statutory interest at the rate of six
percent (6%) per annum from the date such funds were remitted to Korea, and PHIA shall immediately assign and transfer all of its shares
in the Company to the Investor.

10.3 In the event the Company terminates this Agreement as a result of a breach by the Investor, the Investor agrees that, in addition to Section 10.1, all
funds paid by the Investor to date shall be forfeited and applied as consideration for the purchase of the Company's shares held
by PHIA.

.

**Article 11 (Notices)**

All notices shall be sent to the following addresses:

**Company**:

Intromedic Co., Ltd. Attn: Yong Seok CHO

Suite 1106, 41.Digital-ro 31-gil Guro-gu, Seoul 08375 Korea

T: 2 801 9300 / Cell:10 5294 8492

Email:cys8492@intromedic.com

**Investor**:

FirstVitals, Inc. Ernie G. Lee

2605 Camino Tassajara #2500, Danville, CA 94526, USA

T: +1-800-922-8844 ext. 8888 \| F: +1-800-750-3940 \|

Google Voice: +1-925-209-7555

Email: ernie.lee@proteusdx.com

**Article 12 (Confidentiality)**

Neither party shall disclose this Agreement or related information to any third party without prior written consent, except where disclosure is required by law or regulation,

provided the other party is given an opportunity to comment beforehand.

**Article 13 (Governing Law and Jurisdiction)**

This Agreement shall be governed by the laws of the Republic of Korea. The Seoul Central District Court shall have exclusive jurisdiction.

**Article 14 (Execution of English Version and Priority**)

This Agreement shall be executed in Korean and English, two originals of each. In case of inconsistency, the Korean version shall prevail, and the English version shall be valid only to the extent not inconsistent.

IN WITNESS WHEREOF, this Agreement has been executed in two originals in both Korean and English, each party retaining one original in each language.

[Company] Intromedic Co., Ltd.

CEO: /s/ Yong Seok Cho

[Investor] FirstVitals, Inc.

Representative: /s/ Ernie G. Lee

## Ex1U-1

**Exhibit 1U-1.3**

**SHARE PURCHASE AGREEMENT**

This Agreement is entered into on September 30, 2025, by and between:

**Transferor**: Port Hamilton Investment Association, a partnership established under the laws of the Republic of Korea, having its principal office in Seoul (hereinafter, the

"Transferor").

**Transferee**: FirstVitals, Inc., a corporation incorporated under the laws of the State of Delaware, U.S.A., having its principal office at 8 The Green, Dover, Delaware 19901 (hereinafter, the "Transferee").

**RECITALS**

The Transferor is the largest shareholder of Intromedic Co., Ltd. (the "Company"), a corporation having its principal office at #1105–1106, 41, Digital-ro 31-gil, Guro-gu, Seoul, Korea (CEO: Yong Seok Cho), holding 4,216,867 shares out of the Company's total issued shares of 42,997,901. Spring Nine Co., Ltd. ("Spring Nine") is the second largest shareholder, holding 1,807,228 shares.

The shares are electronically registered under the Electronic Registration of Stocks, Bonds, etc. Act, and no physical share certificates have been issued.

The Company was listed on the KOSDAQ Market of the Korea Exchange on December 19, 2013. However, on May 13, 2025, the KOSDAQ Listing Committee resolved to delist the Company. The Company filed an injunction with the Seoul Southern District Court on May 14, 2025, to suspend the effectiveness of the delisting decision. Until the court rules on the injunction, trading of the shares remains suspended.

On July 24, 2025, the Board of Directors of the Company resolved to convene an extraordinary shareholders' meeting on August 8, 2025, to amend the Articles of Incorporation. Although notice was duly given, the meeting was not validly convened due to a lack of quorum.

**Article 1 (Purpose)**

The Transferor agrees to transfer a portion of its shares to the Transferee and to delegate the voting rights of the remaining shares to the Transferee, thereby enabling the Transferee to exercise management control over the Company.

**Article 2 (Transferred Shares)**

Of the 4,216,867 ordinary registered voting shares (par value KRW 100 per share) held by the Transferor, 2,727,273 shares (the "Transferred Shares") shall be transferred to the Transferee.

**Article 3 (Purchase Price)**

The purchase price of the Transferred Shares shall be KRW 1,100 per share, totaling KRW 3,000,000,000 (fractions under KRW 1,000 truncated).

**Article 4 (Payment of Purchase Price)**

4.1 Subject to satisfaction of the conditions precedent under Article 7, the Transferee shall deposit KRW 300,000,000 on September 30, 2025, into a domestic account opened in the name of the Transferee pursuant to an Account Management Agreement entered into among the Transferor, the Transferee, and Law Firm Gilsang.

Bank <u>Account Holder</u> <br> <u>KB Kookmin Bank</u> <u>FirstVitals, Inc</u>

4.2 The remaining KRW 2,700,000,000 shall be deposited into the same account on October 30, 2025.

4.3 Absent any breach by the Transferor, the full KRW 3,000,000,000 shall then be transferred from such account on November 14, 2025, to the account designated by the Transferor, whereupon the Transferor shall perform all procedures for registration of the Transferee as the shareholder of the Transferred Shares.

Bank <u>Account NO.</u> <u>Account Holder</u> <br> <u>MIRAE ASSET</u> <u>776 1220 4116 0</u> <u>Port Hamilton Investment Association</u>

**Article 5 (Transferor's Obligation to Purchase Shares)**

5.1 By November 12, 2025, the Transferor shall enter into a share purchase agreement with Spring Nine to purchase all 1,807,228 shares held by Spring Nine by November 12, 2025.

5.2 The Transferor shall provide a copy of such agreement to the Transferee's agent by November 12, 2025.

5.3 If not provided, the Transferee may either deem such failure to constitute a material breach by the Transferor and terminate this Agreement in accordance with Article 11, or withhold payment of the purchase price under Article 4.3 until the copy is submitted.

5.4 Voting rights for the shares acquired from Spring Nine must also be delegated to the Transferee pursuant to Article 6.

**Article 6 (Transferor's Obligation to Convene Shareholders' Meeting)**

6.1 After the Transferee deposits KRW 300,000,000 on September 30, 2025, the

Transferor shall promptly convene a board meeting of the Company to resolve to hold an extraordinary shareholders' meeting on November 14, 2025, for the purpose of appointing the directors and auditor designated by the Transferee, and shall duly give notice to all shareholders.

6.2 If the nominees are not appointed at the November 14, 2025. meeting, the Transferee may rescind this Agreement and also rescind the Share Subscription Agreement to be entered into between the Company and the Transferee.

**Article 7 (Conditions Precedent)**

Before the Transferee pays the purchase price, the Transferor shall satisfy the following conditions, unless expressly waived in writing by the Transferee:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) Delivery to the Transferee's agent of an irrevocable proxy with a seal certificate, permanently delegating all voting rights
attached to the remaining shares (other than the Transferred Shares) to the Transferee, effective even if such shares are transferred
to a third party; to be delivered upon the Transferee's deposit of KRW 300,000,000 on September 30, 2025.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) Delivery to the Transferee's agent of resignation letters of all directors and auditors of the Company, with seal certificates
attached, upon the Transferee's deposit of KRW 2,700,000,000 on November 14, 2025.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii) Delivery of tax payment certificates evidencing full payment of all national and local taxes.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iv) Delivery of a statement of liabilities of the Company as of the date of this Agreement, including all debts owed to financial institutions
or individuals, unpaid wages, and outstanding notes or checks.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(v) Delivery of a copy of the share purchase agreement entered into with Spring Nine, together with the designated account details of
Spring Nine for receipt of the share purchase price.

**Article 8 (Transferor's Representations and Warranties)**

&nbsp;&nbsp;&nbsp;&nbsp;8.1 As of the date of this Agreement, the Transferor represents and warrants that:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1. The Company is duly incorporated and validly existing under the laws of the Republic of Korea, has obtained all necessary permits,
approvals, and registrations, and is not subject to invalidation.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2. Neither the Articles of Incorporation nor applicable laws impose any legal or factual restrictions on the transfer of the Transferred
Shares.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3. The Transferor is the lawful owner of the shares, has full authority to transfer them and to delegate voting rights, has completed
all internal procedures, and the shares are free from encumbrances.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4. The Company has no liabilities other than those disclosed in the statement of liabilities and has no outstanding notes or checks.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5. Miropet Co., Ltd. has failed to perform its obligations under certain agency agreements with the Company (covering Korea, the Americas,
Europe, and Asia), and the Company retains the right to terminate such agreements.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6. The Share Purchase Agreement, the Voting Rights Proxy Agreement, and the Account Management Agreement entered into by and between
the Transferee and the Transferor on the date hereof shall remain valid and in full force and effect as of November 15, 2025, and shall
not have been terminated prior to such date as a result of any default by the Transferor.

&nbsp;&nbsp;&nbsp;&nbsp;8.2 If any of the above warranties is untrue and frustrates the purpose of this Agreement, the Transferee may terminate this Agreement
by written notice within 10 days, and the Transferor shall compensate all damages.

**Article 9 (Transferee's Representations)**

9.1 The Transferee represents that it is duly incorporated under Delaware law and has obtained all necessary approvals to acquire the
Transferred Shares, with no legal or factual impediments.

9.2 If breached, the Transferor may terminate this Agreement by written notice within 10 days and recover damages.

**Article 10 (Costs and Taxes)**

Each party shall bear its own costs and taxes arising under this Agreement as of the date of payment of the purchase price.

**Article 11 (Termination)**

11.1 Either party may terminate this Agreement by written notice if the other party breaches this Agreement, and the breaching party shall compensate all damages suffered.

11.2 In the event the Transferee terminates this Agreement as a result of a breach by the Company or the Transferor, the Company and Transferor each agrees that, in addition to Section 11.1, all funds paid by the Transferee shall be returned to the Transferee together with statutory interest at the rate of six percent (6%) per annum from the date such funds were remitted to Korea, and the Transferor shall immediately assign and transfer all of its shares in the Company to the Transferee.

11.3 In the event the Transferor terminates this Agreement as a result of a breach by the Transferee, the Transferee agrees that, in addition to Section 11.1, all funds paid by the Transferee to date shall be forfeited and applied as consideration for the purchase of the Company's shares held by the Transferor.

**Article 12 (Notices)**

All notices shall be deemed delivered when sent by email or mail to the following:

**Transferor:**

Port Hamilton Investment Association Yong Seok CHO

1506. 15F Seocho LG Eclat 71 Banpo-daero 14-gil, Seocho-gu, Seoul, Korea

Email: cys8492@intromedic.com

**Transferee**:

FirstVitals, Inc. Ernie G. Lee

2605 Camino Tassajara #2500, Danville, CA 94526, USA

T: +1-800-922-8844 ext. 8888 \| Google Voice: +1-925-209-7555

Email: ernie.lee@proteusdx.com

**Article 13 (Confidentiality)**

Neither party shall disclose the contents of this Agreement or related information to any third party without prior written consent, except where disclosure is required by law, stock exchange regulations, or governmental authorities, in which case the disclosing party shall first provide the other party an opportunity to comment.

**Article 14 (Governing Law and Jurisdiction)**

14.1 This Agreement shall be governed by and construed in accordance with the laws of the Republic of Korea.

14.2 The Seoul Central District Court shall have exclusive jurisdiction over all disputes.

**Article 15 (Execution of English Version and Priority)**

15.1 This Agreement shall be executed in both Korean and English, two (2) originals of each, with each party retaining one (1) original in each language.

15.2 In case of conflict, the Korean version shall prevail, and the English version shall be valid only to the extent not inconsistent with the Korean version.

IN WITNESS WHEREOF, the parties have executed this Agreement in two originals in both Korean and English, each party retaining one copy in each language.

**[TRANSFEROR]**

Port Hamilton Investment Association

1506. 15F Seocho LG Eclat, 71 Banpo-daero 14-gil, Seocho-gu, Seoul, Republic of Korea

By: /s/ Yong Seok Cho.

**TRANSFEREE**

FirstVitals, Inc.

8 The Green, Dover, Delaware 19901, U.S.A.

By: /s/ Ernie G. Lee

## Ex1U-6

**Exhibit 1U-6.7**

**THIS NOTE AND THE SECURITIES ISSUABLE UPON CONVERSION HEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED ("ACT"), NOR HAVE THEY BEEN REGISTERED OR QUALIFIED UNDER THE SECURITIES LAWS OF ANY STATE. NEITHER THIS NOTE NOR THE SECURITIES ISSUABLE UPON ITS CONVERSION MAY BE SOLD, TRANSFERRED, HYPOTHECATED, OR OTHERWISE DISPOSED OF UNLESS A REGISTRATION STATEMENT UNDER THE ACT IS IN EFFECT AS TO SUCH TRANSFER, THE TRANSFER IS MADE IN ACCORDANCE WITH RULE 144 UNDER THE ACT OR AS OTHERWISE PERMITTED BY BORROWER, OR, IN THE OPINION OF COUNSEL SATISFACTORY TO BORROWER, REGISTRATION UNDER THE ACT IS UNNECESSARY IN ORDER FOR SUCH TRANSFER TO COMPLY WITH THE ACT AND WITH APPLICABLE STATE SECURITIES LAWS. THIS NOTE HAS BEEN ISSUED IN RELIANCE UPON THE EXEMPTION FROM REGISTRATION PROVIDED IN REGULATION D, RULE 506 OF THE ACT. THIS PROMISSORY NOTE IS NOT NEGOTIABLE OR TRANSFERABLE IN ANY WAY WITHOUT THE WRITTEN CONSENT OF THE BORROWER OF SUCH PROMISSORY NOTE, REFERRED TO AS THE "BORROWER" BELOW, WHICH CONSENT MAY BE GRANTED OR WITHHELD IN BORROWER'S SOLE DISCRETION. IT IS UNLAWFUL TO CONSUMMATE A SALE OR TRANSFER OR ENDORSEMENT OF THIS PROMISSORY NOTE WITHOUT FIRST OBTAINING SUCH CONSENT. BEFORE DECIDING WHETHER TO GRANT CONSENT TO SUCH A TRANSFER, BORROWER MUST ALSO RECEIVE AN OPINION OF COUNSEL ACCEPTABLE TO THE BORROWER OF THIS PROMISSORY NOTE AND ADDRESSED TO THE BORROWER OF THIS PROMISSORY NOTE THAT THE PROPOSED TRANSFER OR SALE OF THIS PROMISSORY NOTE WOULD NOT AFFECT THE ORIGINAL SALE OF SECURITIES BY THE BORROWER OF THIS PROMISSORY NOTE PURSUANT TO THE EXEMPTION FROM REGISTRATION PROVIDED BY SEC RULE 506 AND THAT THE TRANSFER WOULD BE IN COMPLIANCE WITH ALL APPLICABLE STATE OR FEDERAL SECURITIES LAWS.**

**FIRSTVITALS INC.**

**SERIES A CONVERTIBLE PROMISSORY NOTE**

---

| | |
|:---|:---|
| Principal Amount:<br> $250,000.00 | <br> October 2, 2025 |

---

For value received, the undersigned, FirstVitals Inc., a Delaware corporation ("***Borrower***" or "***Company***"), hereby promises to pay to Dr. Steven Gest ("***Lender***"), in lawful money of the United States of America, the principal sum of two hundred fifty thousand dollars ($250,000.00) (the "***Note Amount***" or "***Loan***"), or such lesser principal amount as may be outstanding under this Series A Convertible Promissory Note (the "***Note***"), plus interest thereon from the date hereof on the aggregate unpaid principal amount until such amount is paid in full or this Note in converted as described herein below.

1. <u>Principal and Interest</u>. Amounts owed hereunder and disbursed to the Borrower shall bear interest
at the rate of ten percent (10.0%) per annum (calculated on the basis of a 365 day year). In the event this Note has not been converted
as described herein, all principal and interest due hereunder shall be due and payable in a single, lump sum payment on March 17, 2028
(the "  ***Maturity Date*** "), or on such later date as may be mutually agreed by the parties. All interest payments
shall accrue and not be payable until the Maturity Date. The Company has the right to extend this Note for a period of one year from the
Maturity Date by giving the Lender notice not less than 10 days prior to the Maturity Date. During the one-year extension, all provisions
of this Note including the Conversion and no Interest provisions shall remain valid and enforceable. The Company can prepay this Note
at any time.

2. <u>Disbursement</u>. On the date of execution of this Note by Borrower, Lender shall disburse $250,000.00
to Borrower via electronic or wire transfer.

3. <u>Permitted Uses</u>. The proceeds of the Loan may be used for payment of Permitted Expenses, as defined
herein. As used herein, the term Permitted Expenses means reasonable and customary operating expenses and capital expenditures related
to the ongoing operation of the Borrower including costs for operations, acquisitions, product development, marketing, legal fees, administrative
fees and all other expenses approved by the Chief Executive Officer of the Company.

4. <u>Conversion</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a. <u>Upon the Company's Initial Public Offering.</u> The Company shall have the option to convert the Note in common shares of the Company at any time after the effectiveness of a registration statement filed with the Securities and Exchange Commission pursuant to the 1933 Securities Act. The Company shall be permitted to include all common shares issuable upon conversion of the Note in the registration statement. The common shares issuable upon conversion shall be referred to as "***Conversion Shares***"

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b. <u>Conversion Formula</u>. Unless separately negotiated, the Company shall convert the Note into Conversion Shares at a 50% discount to the pricing of the common shares as offered under the effective registration statement described in Section 4(a).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;c. <u>Conversion Upon an Alternative Financing Transaction</u>. If the Company determines not to offer its common shares in an initial public offering described in Section 4(a), the Company may still convert the Note pursuant to an Alternative Financing Transaction. At the closing of an Alternative Financing Transaction, the Note shall automatically convert into Conversion Shares at 50% of the value of the Company's common shares, as valued in the Alternative Financing Transaction. In the event the value cannot be determined in the Alternative Financing Transaction, the Board of Directors of the Company shall determine, at their reasonable discretion, the value of the Company's common shares. An Alternative Financing Transaction is an equity financing that raises proceeds to the Company in excess of $30M (thirty million dollars).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;d. <u>Conversion Notice</u>. The Company shall provide written notice of pending conversion to the Lender at least ten days prior to such conversion.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;e. <u>Issuance of Conversion Shares</u>. As soon as practicable after conversion of this Note, the Company will cause to be issued in the name of and delivered to the Lender, a certificate or certificates, a capitalization table, or other instruments, for the number or amount, as applicable, of Conversion Shares issued in a conversion to which the Lender is entitled upon such conversion under the terms of this Note. No fractional equity interests will be issued upon conversion of this Note. If upon any conversion of this Note (and all other Notes held by the same Lender, after aggregating all such conversions), a fraction of a share would otherwise result, then in lieu of such fractional shares the Company will issue to Lender an additional Conversion Share.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;f. <u>Adjustment Provisions</u>. The number and character of shares of Conversion Shares issuable upon conversion of this Note (or any shares of stock or other securities or property at the time receivable or issuable upon conversion of this Note) and the conversion price therefor, are subject to adjustment upon occurrence of the following events between the date this Note is issued and the date it is converted:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;i. <u>Adjustment for Splits, Recapitalizations, etc.</u> The number or amount, as applicable, of Conversion Shares issuable upon conversion of this Note (or any other securities at the time issuable upon conversion of this Note) shall each be proportionally adjusted to reflect any split, reclassification, recapitalization or other similar event affecting the number or amount of outstanding Shares unless the conversion ratio of such Conversion Shares already reflects such event.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ii. <u>Notice of Adjustments</u>. The Borrower shall promptly give written notice of each adjustment or readjustment of the conversion price or the number of Conversion Shares or other securities issuable upon conversion of this Note. The notice shall describe the adjustment or readjustment and show in reasonable detail the facts on which the adjustment or readjustment is based.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;iii. <u>No Change Necessary</u>. The form of this Note need not be changed because of any adjustment in the conversion price or in the number of shares of Conversion Shares issuable upon its conversion.

5. <u>Representations and Warranties</u>. As an inducement to the Lender to make the Loan, the Borrower represents and warrants to the
Lender that:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a. The Borrower is duly organized, validly existing and in good standing as a corporation under the laws of the State of Delaware and:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;i. has the power and authority and the legal right to own and operate its property and to conduct business in the manner in which it does and proposes so to do, and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ii. is in compliance in all material respects with all requirements of law and contractual obligations.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b. The Borrower has the power and authority and the legal right to execute, deliver and perform pursuant to the terms and conditions of this Note and has taken all necessary corporate action to authorize the execution, delivery and performance under the terms of this Note. This Note has been duly executed and delivered on behalf of the Borrower and constitutes the legal, valid and binding obligation of the Borrower enforceable against the Borrower in accordance with its terms, subject to the effect of applicable bankruptcy and other similar laws affecting the rights of creditors generally and the effect of equitable principles whether applied in an action at law or a suit in equity.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;c. The execution, delivery and performance of this Note, the borrowing hereunder and the use of the proceeds hereof, will not violate any provision of Borrower's Articles of Incorporation, Bylaws or requirement of law or any contractual obligations of the Borrower or create or result in the creation of any lien on any assets of the Borrower.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;d. <u>Affirmative Covenants</u>; Lender Acknowledgement; Lender Representation. The Lender hereby represents and warrants to the Borrower that the Lender:, is an 'accredited investor' as that term is defined in Rule 501 (a) of Regulation D promulgated under the Securities Act.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;e. is acquiring the Note and Conversion Shares for its own account and not with a view towards, or for resale in connection with, the public sale or distribution thereof in violation of applicable securities laws, except pursuant to sales registered or exempted under the 1933 Act. The Lender does not presently have any agreement or understanding, directly or indirectly, with any Person to distribute any the Note or the Conversion Shares in violation of applicable securities laws. For purposes of this Agreement, "**Person**" means an individual, a limited liability company, a partnership, a joint venture, a corporation, a trust, an unincorporated organization, any other entity and any Governmental Entity or any department or agency thereof.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;f. <u>Reliance on Exemptions</u>. The Lender understands that the Note and Conversion Shares are being offered and sold to it in reliance on specific exemptions from the registration requirements of United States federal and state securities laws and that the Company is relying in part upon the truth and accuracy of, and the Lender's compliance with, the representations, warranties, agreements, acknowledgments and understandings of the Lender set forth herein in order to determine the availability of such exemptions and the eligibility of the Lender to acquire the Note and Conversion Shares.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;g. <u>Information</u>. The Lender and his advisors, if any, have been furnished with all materials relating to the business, finances and operations of the Company and materials relating to the offer and sale of the Note and Conversion Shares that have been requested by the Lender. The Lender and his advisors, if any, have been afforded the opportunity to ask questions of the Company. Neither such inquiries nor any other due diligence investigations conducted by the Lender or his advisors, if any, or its representatives shall modify, amend or affect the Lender's right to rely on the Company's representations and warranties contained herein. The Lender understands that his investment in the Note and Conversion Shares involves a high degree of risk. The Lender has sought such accounting, legal and tax advice as it has considered necessary to make an informed investment decision with respect to his acquisition of the Note and Conversion Shares.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;h. <u>No Governmental Review</u>. The Lender understands that no United States federal or state agency or any other government or governmental agency has passed on or made any recommendation or endorsement of the Note and Conversion Shares or the fairness or suitability of the investment in the Note and Conversion Shares nor have such authorities passed upon or endorsed the merits of the offering of the Note and Conversion Shares.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;i. <u>Transfer or Resale</u>. The Lender understands that: (i) the Note and Conversion Shares have not been and are not being registered under the 1933 Act or any state securities laws, and may not be offered for sale, sold, assigned or transferred unless (A) subsequently registered thereunder, (B) the Lender shall have delivered to the Company (if requested by the Company) an opinion of counsel, in a form reasonably acceptable to the Company, to the effect that such Note and Conversion Shares to be sold, assigned or transferred may be sold, assigned or transferred pursuant to an exemption from such registration, or (C) the Lender provides the Company with reasonable assurance that such Note and Conversion Shares can be sold, assigned or transferred pursuant to Rule 144 or Rule 144A promulgated under the 1933 Act (or a successor rule thereto) (collectively, "**Rule 144**"); (ii) any sale of the Note and Conversion Shares made in reliance on Rule 144 may be made only in accordance with the terms of Rule 144, and further, if Rule 144 is not applicable, any resale of the Note and Conversion Shares under circumstances in which the seller (or the Person through whom the sale is made) may be deemed to be an underwriter (as that term is defined in the 1933 Act) may require compliance with some other exemption under the 1933 Act or the rules and regulations of the SEC promulgated thereunder; and (iii) except as otherwise set forth herein, neither the Company nor any other Person is under any obligation to register the Note and Conversion Shares under the 1933 Act or any state securities laws or to comply with the terms and conditions of any exemption thereunder. Notwithstanding the foregoing, the Note and Conversion Shares may be pledged in connection with a bona fide margin account or other loan or financing arrangement secured by the Note and Conversion Shares and such pledge of the Note and Conversion Shares shall not be deemed to be a transfer, sale or assignment of the Note and Conversion Shares hereunder, and if the Lender effects a pledge of Note and Conversion Shares, the Lender will not be required to provide the Company with any notice thereof or otherwise make any delivery to the Company pursuant to this Agreement, including, without limitation, this Section 8(g).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;j. <u>Validity; Enforcement</u>. This Note has been duly and validly authorized, executed and delivered on behalf of the Lender and shall constitute the legal, valid and binding obligations of the Lender enforceable against the Lender in accordance with their respective terms, except as such enforceability may be limited by general principles of equity or to applicable bankruptcy, insolvency, reorganization, moratorium, liquidation and other similar laws relating to, or affecting generally, the enforcement of applicable creditors' rights and remedies.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;k. <u>No Conflicts</u>. The execution, delivery and performance by the Lender of this Agreement and the consummation by the Lender of the transactions contemplated hereby and thereby will not (i) result in a violation of the organizational documents of the Lender, or (ii) conflict with, or constitute a default (or an event which with notice or lapse of time or both would become a default) under, or give to others any rights of termination, amendment, acceleration or cancellation of, any agreement, indenture or instrument to which the Lender is a party, or (iii) result in a violation of any law, rule, regulation, order, judgment or decree (including federal and state securities laws) applicable to the Lender, except in the case of clauses (ii) and (iii) above, for such conflicts, defaults, rights or violations which could not, individually or in the aggregate, reasonably be expected to have a material adverse effect on the ability of the Lender to perform its obligations hereunder.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;l. <u>Experience of the Lender</u>. The Lender, either alone or together with its representatives, has such knowledge, sophistication and experience in business and financial matters so as to be capable of evaluating the merits and risks of the prospective investment in the Note and Conversion Shares, and has so evaluated the merits and risks of such investment. The Lender is able to bear the economic risk of an investment in the Note and Conversion Shares and, at the present time, is able to afford a complete loss of such investment.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;m. <u>General Solicitation</u>. Such Lender is not purchasing the Note and Conversion Shares as a result of any advertisement, article, notice or other communication regarding the Note and Conversion Shares published in any newspaper, magazine or similar media or broadcast over television or radio or presented at any seminar or any other general solicitation or general advertisement.

6. <u>Events of Default</u>. Upon the occurrence of any of the following events (each, an "Event of
Default"):

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a. The Borrower shall fail to pay any amount due under this Note within five (5) days of the due date;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b. Any representation or warranty made by the Borrower in this Note shall be materially inaccurate or incomplete; provided, that any such inaccurate or incomplete representation or warranty shall not constitute an Event of Default if it is corrected within thirty (30) days after any officer or employee of the Borrower obtains knowledge of such inaccuracy or incompleteness, and the corrected or revised representation or warranty made by the Borrower is acceptable to the Lender;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;c. The Borrower shall fail to observe or perform in any material respect any of the other terms or provisions of this Note and such failure shall continue for thirty (30) days;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;d. The Borrower shall:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;i. commence any case, proceeding or other action under any existing or future law of any jurisdiction, domestic or foreign, relating to bankruptcy, insolvency, reorganization or relief of debtors, seeking to have an order for relief entered with respect to it, or seeking to adjudicate it a bankrupt or insolvent, or seeking reorganization, arrangement, adjustment, winding-up, liquidation, dissolution, composition or other relief with respect to it or its debts, or

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ii. commence any case, proceeding or other action seeking appointment of a receiver, trustee, custodian or other similar official for it or for all or any substantial part of its assets, or

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;iii. make a general assignment for the benefit of its creditors.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;e. THEN, automatically upon the occurrence of an Event of Default under clause (d) of this Section 7 and, in all other cases, at the option of the Lender, in each case without notice to or demand upon the Borrower or any other party, the entire principal balance hereof thereon shall become immediately due and payable.

7. <u>Waivers by the Borrower; No Setoffs or Counterclaims</u>. The Borrower and its successors and assigns,
hereby waive presentment, demand, protest and notice thereof or of dishonor, and agree that it shall remain liable for all amounts due
hereunder notwithstanding any extension of time or change in the terms of payment of this Note granted by the Lender or any delay or failure
by the Lender to exercise any rights under this Note. All payments required by this Note shall be made without setoff or counterclaim.

8. <u>Assignment</u>. The parties may not assign their rights or obligations under this Note without the
prior written consent of the other Party and any such purported assignment by one party without obtaining the prior written consent of
the other party shall be void ab initio. This Note shall inure to the heirs, legal representatives, and successors of the Lender.

9. <u>Notices</u>. All notices given by the Borrower or the Lender hereunder to the other shall be in writing,
delivered personally or by depositing the same in the United States mail, registered, with postage prepaid, addressed as follows:

<u>Lender</u>:

[Address]

<u>Borrower</u>:

2605 Camino Tassajara #2500 \|

Danville, CA 94526

Ernie.Lee@firstvitals.com

Either the Lender or the Borrower may change the address to which notices are to be sent by notice of such change to the other given as provided herein. Such notices shall be effective on the date received or, if mailed, on the third business day following the date mailed.

10. <u>Governing Law</u>. This Note is governed by the laws of the State of California, without regard to
the choice of law rules of that State. Each party agrees that all legal proceedings concerning the interpretations, enforcement and defense
of the transactions contemplated by this Note shall be commenced exclusively in the state and federal courts in California. Each party
hereby irrevocably submits to the exclusive jurisdiction of the state and federal courts in the State of California for the adjudication
of any dispute hereunder, and hereby irrevocably waives, and agrees not to assert in any suit, action or proceeding, any claim that it
is not personally subject to the jurisdiction of any such court, that such suit, action or proceeding is improper or is an inconvenient
venue for such proceeding.

11. <u>Alternative Dispute Resolution</u>. In the event of any dispute related to this Note, the parties agree
to initially resolve such dispute by mediation administered by JAMS and mediated in Contra Costa county, California. Each party shall
agree to pay 50% of the costs of mediation. In the event mediation does not resolve the matter, any disputes arising under this Agreement
shall be resolved through binding arbitration administered by JAMS in accordance with its Comprehensive Arbitration Rules & Procedures.
Arbitration shall be the mandatory and exclusive means for resolving disputes, and the arbitration shall take place virtually or, if agreed
upon by all parties, in person in Contra Costa county, California, or at any other location mutually agreed upon. The complaining party
shall be responsible for any arbitration fees. Arbitration shall be limited to resolving the specific dispute between the Company and
the Lender. The arbitrator shall not have the authority to award punitive damages, or any remedy beyond actual, documented losses, but
shall have the authority to award the reasonable attorney fees and legal costs to the prevailing party in an arbitration

12. <u>Waiver of Jury Trial and Governing Law</u>. THE BORROWER HEREBY WAIVES ANY RIGHT TO HAVE A JURY PARTICIPATE
IN RESOLVING ANY DISPUTE, WHETHER SOUNDING IN CONTRACT, TORT OR OTHERWISE ARISING OUT OF, CONNECTED WITH, RELATED TO OR INCIDENTAL TO
THIS NOTE. INSTEAD, ANY DISPUTES RESOLVED IN COURT WILL BE RESOLVED IN A BENCH TRIAL WITHOUT A JURY. All questions concerning the construction,
validity, enforcement and interpretation of the Note shall be governed by and construed and enforced in accordance with the internal laws
of the State of California, without regard to the principles of conflicts of law thereof. Nothing contained herein shall be deemed to
limit in any way any right to serve process in any other manner permitted by law.

13. <u>Further Assurances</u>. Each party shall do and perform, or cause to be done and performed, all such
further acts and things, and shall execute and deliver all such other agreements, certificates, instruments and documents, as any other
party may reasonably request in order to carry out the intent and accomplish the purposes of this Agreement and the consummation of the
transactions contemplated hereby.

IN WITNESS WHEREOF, the Company and Lender has caused this Note to be duly executed the day and year first above written.

---

| | |
|:---|:---|
| **FIRSTVITALS INC,** a<br> Delaware corporation<br> /s/ Ernest G. Lee | **Dr. Steven Gest**<br>**/**s/ Steven Gest |
| By: Ernest G. Lee<br>|  |
| Title: Chief Executive<br> Officer |  |

---